Emergent Challenges in Biopharma Portfolio Management

In 2023, Planview was pleased to sponsor several WHY Summit Events: Basil, Switzerland, and Philadelphia. A year later, we returned to Philadelphia and then headed cross-country to San Francisco for the WHY Summit’s 21st and 22nd American Pharma and Biotech Project, Program, and Portfolio Management Conference. In this blog, we will illuminate a few common...

Top 5 Questions About the Project to Product Shift

Discover what’s top of mind for leaders and teams focused on creating and delivering business value. Plus: Share your insights with the all-new Project to Product State of the Industry survey.

7 Reasons to Cut Tech Bloat

Learn how untangling your tech stack can lead to more wins with greater speed without tripping up your strategy.

Three Key Elements for Achieving Strategic Portfolio Management Excellence

Choosing the best strategic portfolio management (SPM) solution for your enterprise can be tough, but it’s a topic at the forefront of many business leaders’ minds. In research conducted by Economist Impact, commissioned by Planview, 86% of executives believe their organization needs to improve accountability in strategy implementation. However, according to Gartner, “only 13% of...

Should You Build or Buy Your Generative AI Solution?

More than a year after the unveiling of ChatGPT, enterprises are cautiously introducing large language model-driven applications for a multitude of once-miraculous tasks. Explore the pros and cons on both sides of the build vs. buy argument, plus common use cases to support your GenAI aspirations.